Browse News
Filter News
Found 3 articles
-
Big Cypress Acquisition Corp Announces Special Meeting of Stockholders to Approve Business Combination with SAB Biotherapeutics
9/23/2021
Big Cypress Acquisition Corp announced that it will hold a Special Meeting of stockholders to, among other matters, allow its stockholders to approve the proposed business combination with SAB Biotherapeutics, Inc..
-
The business combination agreement will advance SAB’s proprietary platform to develop antibody therapies for immune system disorders and other diseases.
-
SAB Biotherapeutics to List on Nasdaq through Merger with Big Cypress Acquisition Corp., Advancing Unique Human Antibody Platform with Demonstrated Utility in Immunotherapy and Rapid Response to Emerging Diseases
6/22/2021
SAB Biotherapeutics, a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces targeted, high potency, fully-human polyclonal antibodies at scale, and Big Cypress Acquisition Corp., a blank check company focused on innovative biopharmaceutical firms, announced that they have entered into a definitive business combination agreement.